{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-041238","form_type":"8-K/A","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.007706+00:00","generated_at":"2026-06-17T06:27:02.521810+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Carisma FY2022 net loss $61.2M, rev $9.8M; merger closed","bullets":["Net loss of $61.2M for year ended Dec 31, 2022 (basic EPS $54.65 loss); compared to $40.8M net loss in 2021.","Total revenue of $9.8M from collaboration with Moderna; no revenue in 2021.","Cash, equivalents, marketable securities $52.0M at Dec 31, 2022; plus $105.3M net from merger and pre-closing financing.","Merger with Sesen Bio closed March 7, 2023; combined company renamed Carisma Therapeutics Inc.","Accumulated deficit $158.2M as of Dec 31, 2022; management expects cash runway through end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-041238","json":"https://secwatch.observer/filing/0001104659-23-041238.json","markdown":"https://secwatch.observer/filing/0001104659-23-041238.md","text":"https://secwatch.observer/filing/0001104659-23-041238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/0001104659-23-041238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/tm239286d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:27:02.521810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cd4ea06a712db07f3ce1a45d10e35e38507272a","claim":"Carisma Therapeutics Inc. reported the year ended December 31, 2022 results: revenue $ 9,834, net income $ (61,226 ), EPS $ (54.65 ).","evidence_excerpt":"INC. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) Year Ended December 31, 2022 2021 Collaboration revenues $ 9,834 $ — Operating expenses: Research and development 56,618 34,387 General and administrative 9,378 6,407 Total operating expenses 65,996 40,794 Operating loss (56,162 ) (40,794 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/0001104659-23-041238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$ 9,834"},{"label":"Net income","value":"$ (61,226 )"},{"label":"EPS","value":"$ (54.65 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}